AdaptHealth/$AHCO
1D1W1MYTD1Y5YMAX
Capital at risk
About AdaptHealth
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
- Ticker
- $AHCO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 10,900
- Headquarters
- Conshohocken, United States
- Website
- adapthealth.com
AdaptHealth Metrics
BasicAdvanced
$866M
-
-$1.68
1.46
-
Price and volume
Market cap
$866M
Beta
1.46
52-week high
$13.43
52-week low
$5.21
Average daily volume
3.8M
Financial strength
Current ratio
1.124
Quick ratio
0.636
Long term debt to equity
144.389
Total debt to equity
148.969
Interest coverage (TTM)
1.56%
Profitability
EBITDA (TTM)
590.569
Gross margin (TTM)
20.26%
Net profit margin (TTM)
-6.79%
Operating margin (TTM)
4.71%
Effective tax rate (TTM)
3.32%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
2.28%
Return on equity (TTM)
-15.22%
Valuation
Price to revenue (TTM)
0.262
Price to book
0.62
Price to tangible book (TTM)
-0.85
Price to free cash flow (TTM)
9.014
Free cash flow yield (TTM)
11.09%
Free cash flow per share (TTM)
0.72
Growth
Revenue change (TTM)
13.47%
Earnings per share change (TTM)
-410.82%
3-year revenue growth (CAGR)
3.04%
3-year earnings per share growth (CAGR)
123.36%
What the Analysts think about AdaptHealth
Analyst ratings (Buy, Hold, Sell) for AdaptHealth stock.
Analyst projections of the future price of AdaptHealth stock.
Bulls say / Bears say
Organic revenue grew 15.9% year-over-year in Q2 2026, reflecting sustained patient and payer demand for AdaptHealth’s core Sleep Health, Respiratory Health, and Wellness-at-Home services. (Investing.com)
The July 19, 2026 agreement to divest its Diabetes Health business to Cardinal Health for $235 million in cash provides significant liquidity to fuel debt reduction and sharpen the company’s focus on higher-margin core segments. (Reuters)
AdaptHealth closed a $1.1 billion senior secured credit facility in April 2026, extending debt maturities, reducing interest costs, and enhancing financial flexibility to support strategic initiatives. (Investing.com)
AdaptHealth slashed its fiscal 2026 revenue guidance to $2.85 billion–$2.89 billion, with a midpoint ~18% below analysts’ $3.49 billion consensus, signaling deeper-than-expected headwinds from capitated contract rollouts and cost pressures. (Reuters)
Adjusted EBITDA fell 3.2% year-over-year to $132.0 million in Q2 2026, underscoring mounting margin compression arising from new capitated agreements and a manufacturer price increase. (Investing.com)
In February 2026 AdaptHealth agreed to a $35 million settlement to resolve investor claims alleging it concealed a fraudulent billing scheme and overstated its diabetes segment growth, highlighting ongoing litigation and compliance risks. (Bloomberg Law)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
AdaptHealth Financial Performance
Revenues and expenses
AdaptHealth Earnings Performance
Company profitability
Upcoming events
No upcoming events
AdaptHealth News
AllArticlesVideos
AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth
MarketBeat4 weeks ago
AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law
Business Wire4 weeks ago
AdaptHealth Corp. to Participate in Upcoming Investor Conferences
Business Wire1 month ago
Funds containing AdaptHealth
AllEURUSDGBP
Fund name | Fund size | $AHCO weighting |
|---|---|---|
iShares Ageing Population€AGED | €823M | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.